[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341650-105":59,"doc-detail-341650-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rupatadine-inhibited-otud3-promotes-dlbcl-progression-and-immune-evasion-through-deubiquitinating-myl12a-and-pd-l1","Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1","","The obstacle to effectively treating diffuse large B-cell lymphoma (DLBCL) is resistance to standard therapies, especially in relapsed or refractory cases. OTUD3 is overexpressed in DLBCL tissues, yet its function remained unclear. This study shows OTUD3 enhances cell survival by deubiquitinating MYL12A and promotes local CD8+ T cell exhaustion by deubiquitinating PD-L1. The OTUD3 inhibitor rupatadine suppresses deubiquitination of MYL12A and PD-L1 via competitive binding, highlighting OTUD3 as a central oncogenic driver and a therapeutic opportunity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rupatadine-inhibited-otud3-promotes-dlbcl-progression-and-immune-evasion-through-deubiquitinating-myl12a-and-pd-l1/341650/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rupatadine-inhibited-otud3-promotes-dlbcl-progression-and-immune-evasion-through-deubiquitinating-myl12a-and-pd-l1/341650.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in DLBCL treatment?","Question",{"text":112,"@type":113},"Standard therapies face resistance in relapsed or refractory DLBCL, leading to poor survival outcomes and the need for new therapeutic targets and approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does OTUD3 promote DLBCL progression according to the findings?",{"text":117,"@type":113},"OTUD3 enhances cell survival by deubiquitinating MYL12A and drives CD8+ T cell exhaustion in the local environment by deubiquitinating PD-L1.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the mechanism and proposed impact of rupatadine in this study?",{"text":121,"@type":113},"Rupatadine inhibits OTUD3 through competitive binding, reducing deubiquitination of both MYL12A and PD-L1. The results support OTUD3 as a central oncogenic driver and suggest clinical application potential for the inhibitor.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341650,1791048524,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nRupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1  \nYing Sui1,2, Ziyang Shen 1,2, Xiaoyou Li 1, Ya Lu1, SiTong Feng1, Rong Ma1, Jianzhong Wu1, Changwen Jing 1, Zhuo Wang1, Jifeng Feng 1,2 ✉ and Haixia Cao 1,2 ✉  \n© The Author(s) 2024  \n\n|  | The obstacle to effectively treating Diffuse Large B-cell Lymphoma (DLBCL) lies in the resistance observed toward standard therapies. Identifying therapeutic targets that prove effective for relapsed or refractory patients poses a signiﬁcant challenge. OTUD3, a deubiquitinase enzyme, is overexpressed in DLBCL tissues. However, its role in DLBCL has not been investigated. Our study has brought to light the multifaceted impact of OTUD3 in DLBCL. Not only does it enhance cell survival through the deubiquitination of MYL12A, but it also induces CD8+ T cell exhaustion within the local environment by deubiquitinating PD-L1 . Our ﬁndings indicate that the OTUD3 inhibitor, Rupatadine, exerts its inﬂuence through competitive binding with OTUD3 . This operation diminishes the deubiquitination of both MYL12A and PD-L1 by OTUD3 . This research unveils the central and oncogenic role of OTUD3 in DLBCL and highlights the potential clinical application value of the OTUD3 inhibitor, Rupatadine. These ﬁndings contribute valuable insights into addressing the challenges of resistant DLBCL cases and offer a promising avenue for further |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| clinical exploration. |  |  |\n|  | Cell Death and Disease (2024)15:561; [https://doi.org/10.1038/s41419-024-06941-x](https://doi.org/10.1038/s41419-024-06941-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nDiffuse large B-cell lymphoma, known as DLBCL, is the most prevalent lymphoma subtype, accounting for ~30–40 percent of all cases [1] . At present, survival rates for relapsed and refractory DLBCL patients who have undergone initial treatment are less than ideal, highlighting the necessity for novel therapeutic targets and approaches [2, 3]. Ubiquitination is a complex and critical process that regulates various cellular biological processes. During cancer progression, ubiquitination leads to the formation of signaling complexes, which is vital in the dynamic regulation of programmed cellular death. The prospects for understanding and developing ubiquitination-related targeted cancer therapies are promising [4, 5]. OTUD3 is a deubiquitinase enzyme that after being demonstrated by Lin Yuan et al in 2015 to be associated with PTEN stability and tumorigenesis, has since been shown to modulate tumor processes in various cancers [6–10] . Nevertheless, the function of OTUD3 in DLBCL has yet to be investigated or reported.  \nThe tumor microenvironment (TME) holds signiﬁcance for genesis and advancement of lymphomas [11, 12] . Examining the inﬂuence of T-cell immune checkpoints on DLBCL cell survival and the outcomes of immunotherapy holds substantial clinical signiﬁcance [13] . The expression of PD-L1 has been substantiated to correlate with a less favorable prognosis in DLBCL patients [14] . Despite being inﬂuenced by factors such as individual patient variation and disease staging, clinical trials of PD-1/PD-L1 monotherapy or combination therapy in relapsed or refractory DLBCL patients have made substantial strides [15, 16] .  \nIn this study, we have undertaken the ﬁrst systematic exploration of how OTUD3 regulates DLBCL cell survival through underlying mechanisms. Furthermore, we have revealed the intercellular regulation of CD8+ T cell exhaustion by OTUD3 in DLBCL cells and its potential mechanisms. Our investigation into OTUD3, along with its inhibitor rupatadine, has shown potential for offering innovative therapeutic choices in the ﬁeld of targeted therapy and immunotherapy for patients with relapsed or refractory DLBCL [17] .  \nMATERIALS AND METHODS ","cbCaihl72OYdIhnf","https://ap.wps.com/l/cbCaihl72OYdIhnf","pdf",10578439,16,"English","# Introduction\n## Clinical challenge in relapsed and refractory DLBCL\n## Role of ubiquitination and OTUD3\n## Tumor microenvironment and PD-L1/immune checkpoints\n# Materials and Methods\n## Patient specimen\n## Cell lines and cell culture\n## CCK-8 assay\n## Lactate dehydrogenase (LDH) assay","[{\"question\":\"What problem does the study address in DLBCL treatment?\",\"answer\":\"Standard therapies face resistance in relapsed or refractory DLBCL, leading to poor survival outcomes and the need for new therapeutic targets and approaches.\"},{\"question\":\"How does OTUD3 promote DLBCL progression according to the findings?\",\"answer\":\"OTUD3 enhances cell survival by deubiquitinating MYL12A and drives CD8+ T cell exhaustion in the local environment by deubiquitinating PD-L1.\"},{\"question\":\"What is the mechanism and proposed impact of rupatadine in this study?\",\"answer\":\"Rupatadine inhibits OTUD3 through competitive binding, reducing deubiquitination of both MYL12A and PD-L1. The results support OTUD3 as a central oncogenic driver and suggest clinical application potential for the inhibitor.\"}]","Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1 | PDF",1790042973,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14f931a166d599033836ce2783f5cd3a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a5238db36fec5fbd60e21562a7f8312.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9306c6fd37c7c347b06221082f32c2b4.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b362b37f75334a45d0c318a48b2a441.webp",980,1301]